Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.48 |
| ▸ | NPC1 | O15118 | 12/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812095 | 0.89 | RAB9A (0.55) | RAB9ANPC1MAPTATMPOLB | |
| SCHEMBL15361982 | 0.88 | RAB9A (0.52) | RAB9ANPC1MAPTATMPOLB | |
| Hydrochloric Acid SCHEMBL3573666 | 0.87 | RAB9A (0.52) | RAB9ANPC1MAPTATMPOLB | |
| SCHEMBL297607 | 0.87 | RAB9A (0.51) | RAB9ANPC1MAPTATMPOLB | |
| SCHEMBL298817 | 0.83 | TRPV1 (0.45) | RAB9ANPC1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL831020 | 0.82 | MAPT (0.41) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL2813166 | 0.81 | RAB9A (0.51) | RAB9ANPC1MAPTATMPOLB | |
| SCHEMBL2814670 | 0.81 | RAB9A (0.55) | RAB9ANPC1MAPTATMPOLB | |
| SCHEMBL3575898 | 0.80 | RAB9A (0.51) | RAB9ANPC1MAPTATMPOLB | |
| SCHEMBL15361993 | 0.79 | RAB9A (0.52) | RAB9ANPC1MAPTATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106401-B1 | DERIVATIVES OF PYRROLOPYRIDINE-2-CARBOXAMIDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-8044066-B2 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | PYCR1, ATP5PD, NQO2 | RAB9A 2865/4885NPC1 2399/4885MAPT 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.